Pregabalin Capsule
Product Images NDC 60219-1314

Product Visual Gallery

This gallery contains 21 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 60219-1314). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Amneal Pharmaceuticals Ny Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

10 (Pregabalin Capsules Us 1)

An illustration showing the formula to calculate creatinine clearance (CLCr), which factors age in years, weight in kilograms, serum creatinine in mg/dL, and a correction factor of 0.85 for female patients. The formula is presented in a clear mathematical expression format.*

FDA Label Image

F-8 (Pregabalin Capsules Us 10)

A line chart depicting the percentage of patients improved plotted against percent improvement in pain from baseline. Four groups are compared: Pregabalin doses of 600 mg, 450 mg, 300 mg daily, and placebo. The lines show a decreasing trend in patient improvement as pain improvement percentage increases.*

FDA Label Image

Fig-9 (Pregabalin Capsules Us 11)

A survival curve chart comparing Pregabalin and Placebo over 180 days. The y-axis shows the estimated percentage of subjects without LTR (loss to response) from 0% to 100%, and the x-axis shows days from 0 to 180. Two lines represent Pregabalin (solid) and Placebo (dashed), illustrating differences in estimated subject response over time.*

FDA Label Image

F-10 (Pregabalin Capsules Us 12)

A line graph comparing the percent of subjects improved over a range of percent improvement from baseline to Week 12, using a Baseline Observation Carried Forward (BOCF) method. Two lines are shown: a solid line representing Pregabalin and a dashed line representing Placebo, indicating higher and more sustained improvement in the Pregabalin group over time.*

FDA Label Image

F-11 (Pregabalin Capsules Us 13)

A line graph comparing the percent of subjects improved over various improvement thresholds from baseline to week 16, using baseline observation carried forward (BOCF). The solid line represents Pregabalin, while the dashed line represents placebo, showing higher improvement percentages for Pregabalin across all thresholds.*

FDA Label Image

25 mg Label (Pregabalin Capsules Us 14)

Label for Pregabalin Capsules 25 mg, a prescription oral capsule product distributed by Amneal Pharmaceuticals LLC. The label states each capsule contains 25 mg pregabalin, with package size of 90 capsules. Storage instructions and dispensing guidance are included, along with the NDC number 60219-1310-9 and Amneal logo.*

FDA Label Image

50 mg Label (Pregabalin Capsules Us 15)

Pregabalin Capsules 50 mg oral capsules label by Amneal Pharmaceuticals LLC. The label indicates each capsule contains 50 mg pregabalin, with a package size of 90 capsules. Directions note to see prescribing information for usual dosage. Storage instructions specify controlled room temperature. The label includes a barcode and states dispensing with a medication guide.*

FDA Label Image

75 mg Label (Pregabalin Capsules Us 16)

Pregabalin Capsules 75 mg oral dosage form label from Amneal Pharmaceuticals LLC. The label states 90 capsules per container with prescription only use. It includes storage instructions and a barcode. The label features the Amneal logo and indicates the NDC 60219-1312-9.*

FDA Label Image

100 mg Label (Pregabalin Capsules Us 17)

Pregabalin Capsules 100 mg oral capsules packaging label from Amneal Pharmaceuticals LLC. The label includes dosage strength, NDC 60219-1313-9, quantity of 90 capsules, storage instructions at controlled room temperature, and distributor information for Amneal Pharmaceuticals in Bridgewater, NJ.*

FDA Label Image

200 mg Label (Pregabalin Capsules Us 18)

Pregabalin Capsules 200 mg label shows a white and purple panel from Amneal Pharmaceuticals LLC. It indicates oral capsules with a count of 90. The label includes storage instructions, NDC 60219-1315-9, and a red capsule image with imprint 'AN 1315'. Distribution details and handling instructions are also present.*

FDA Label Image

225 mg Label (Pregabalin Capsules Us 19)

Pregabalin 225 mg capsules packaging label shows the product name, strength, and dosage form. It includes a small capsule image labeled 'AN 1316,' the quantity of 90 capsules, and specifies it is Rx only. The labeler is Amneal Pharmaceuticals LLC, Bridgewater, NJ. Storage instructions and dispensing details are also visible along with a barcode.*

FDA Label Image

Structure (Pregabalin Capsules Us 2)

Chemical structure of Pregabalin, showing its molecular framework including an amino group, carboxyl group, and hydrocarbon side chains consistent with its known chemical formula.*

FDA Label Image

300 mg Label (Pregabalin Capsules Us 20)

Pregabalin 300 mg capsules label for oral use, distributed by Amneal Pharmaceuticals LLC. The label indicates 90 capsules per container and includes storage instructions between 20° to 25°C with permitted excursions. It features a red and white capsule illustration marked 'AN 1317' and states the product is Rx only.*

FDA Label Image

150 mg Label (Pregabalin Capsules Us 21)

Label for Pregabalin Capsules 150 mg by Amneal Pharmaceuticals LLC. The label specifies the strength as 150 mg per capsule, includes storage instructions (20° to 25°C), and indicates that the package contains 90 capsules. It also displays a barcode and instructions to dispense with a medication guide.*

FDA Label Image

F1 (Pregabalin Capsules Us 3)

A line graph depicting percent improvement in pain from baseline on the x-axis and percent of patients improved on the y-axis. It compares four groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, Pregabalin 25 mg three times a day, and placebo, showing patient improvement percentages across varying levels of pain improvement.*

FDA Label Image

F-2 (Pregabalin Capsules Us 4)

A line graph depicting the percent of patients improved versus percent improvement in pain from baseline. Two lines represent groups receiving Pregabalin 100 mg three times a day and placebo, showing patient improvement trends across increasing percentages of pain relief.*

FDA Label Image

F-3 (Pregabalin Capsules Us 5)

A line graph displaying the percent of patients improved on the y-axis versus percent improvement in pain from baseline on the x-axis. The graph compares Pregabalin capsules at 75 mg, 150 mg, and 300 mg taken twice a day to placebo. The lines show varying degrees of patient improvement correlated to dosage levels.*

FDA Label Image

F-4 (Pregabalin Capsules Us 6)

A line graph comparing the percent of patients improved versus percent improvement in pain from baseline for Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo. The graph shows trends of patient improvement across varying levels of pain reduction with three distinct curves for each treatment.*

FDA Label Image

F-5 (Pregabalin Capsules Us 7)

A line graph showing percent improvement in pain from baseline versus percent of patients improved. It compares three groups: Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo, with Pregabalin 100 mg showing the highest patient improvement and placebo the lowest across the improvement range.*

FDA Label Image

F-6 (Pregabalin Capsules Us 8)

A bar chart comparing responder rates (%) from two studies (E1 and E3) of Pregabalin at various dosages (50 mg/day to 600 mg/day) versus placebo. The graph shows increasing responder rates with higher dosages of Pregabalin, with BID and TID regimens in Study E3, and notes statistically significant differences versus placebo.*

FDA Label Image

F-7 (Pregabalin Capsules Us 9)

A dose-response line graph showing median percentage reduction in seizures from baseline as a function of dose in mg/day, with data points from four studies labeled E1BD, E2TID, E3BD, and E3TID. Significant p-values (≤ 0.0001 or 0.0007) are noted at various dose points, indicating statistical significance compared to placebo.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.